Plain-English translation of NCT05940311 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a brand-new blood test device called the Versilib AMT photonic biosensor that can detect skin cancer markers in your blood with much greater sensitivity than currently available tests. The device looks for two things: a specific genetic mutation called BRAF p.V600E (which is common in melanoma) and a protein marker that is found in melanoma. Researchers will compare how well this new test works compared to two other standard laboratory methods.
Current blood tests for skin cancer aren't sensitive enough to catch all the cancer markers that might be present. This new technology could help doctors detect melanoma earlier and monitor treatment more accurately, which might lead to better outcomes for patients.
You likely qualify if…
You likely don't qualify if…
As a participant, you would visit the research center to have blood drawn—similar to a standard blood test. The researchers will use your blood sample to test the new device and compare its results to two other established laboratory methods. The study is enrolling about 20 people total, and your participation would likely involve a single or small number of visits depending on the study schedule.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Italy
Collaborators
VTT Technical Research Centre, Finland, Institute of Health Information and Statistics of the Czech Republic
Enrollment target
~20 participants
Started
April 2022
Primary completion
November 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Elena Giordani, PhD
Regina Elena Cancer Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.